while not a conflict, there are downsides to "partnering or licensing" to segments of the industry... a piece there & a piece here and pretty soon no one is interested in buying the platform as there are too many pieces to retrieve to give anyone control & the patent limps toward expiration not to mention a competitive assault that could wipe out any advantage in the drug delivery system .. TTNP management is long in the tooth w/out deep pockets to quickly bring anything to market ... they need to sell the company period in order to maximize shareholder value... yes Braeburn should be very upset @ collaboration w/OPNT on using the EVA for antagonist to opiate addiction... Braeburn has spent a fair amount of coin training the MD's who now may have the option to implant either an antagonist or an agonist.. Akin to TTNP & OPNT getting a free ride from Braeburn... ALKS also stands to lose market share if the antagonist is successful... I can see Apple Tree possibly buying TTNP if they continue to support Braeburn, otherwise everyone will limp along if TTNP does not find a buyer.. 3 key things to keep in mind relative to the loan agreement they signed coming up in the short term... by year end they have to meet the following in order to get another 3 mil in 2018: 1. market cap of 50 m (they're close, price >2.5 would do it); 2. royalty income of not < than $750,000 (who knows); 3.Execution of a partnership or similar agreement for the marketing and sale of Probuphine in Europe (if they get EU approval that should suffice)... the short interest decline is a good sign.. many covered, but TTNP needs to FU by aggressively marketing the company for a buyout .. all the rest is noise
